Randomized Multicenter Phase II Trial Comparing Two Schedules of Etirinotecan Pegol (NKTR-102) in Women with Recurrent Platinum-Resistant/refractory Epithelial Ovarian Cancer.
Journal of Clinical Oncology(2013)
AI Read Science
Must-Reading Tree
Example

Generate MRT to find the research sequence of this paper
Chat Paper
Summary is being generated by the instructions you defined